Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBITDA (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBITDA for 15 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 16.22% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.7 million through Dec 2025, down 33.58% year-over-year, with the annual reading at -$7.8 million for FY2025, 391.95% down from the prior year.
  • EBITDA for Q4 2025 was -$2.0 million at Aytu Biopharma, down from -$1.5 million in the prior quarter.
  • The five-year high for EBITDA was $13.7 million in Q2 2023, with the low at -$53.4 million in Q1 2022.
  • Average EBITDA over 5 years is -$7.9 million, with a median of -$2.0 million recorded in 2025.
  • The sharpest move saw EBITDA plummeted 678.72% in 2021, then skyrocketed 251.6% in 2025.
  • Over 5 years, EBITDA stood at -$11.3 million in 2021, then surged by 39.19% to -$6.9 million in 2022, then soared by 145.81% to $3.1 million in 2023, then crashed by 153.88% to -$1.7 million in 2024, then dropped by 16.22% to -$2.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$2.0 million, -$1.5 million, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.